Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00002419 | Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment | PHASE2 | COMPLETED | 25 | — | — | - | - | Jun 24, 2005 | 5 | United States |
| Name | Type | Description |
|---|---|---|
| Abacavir sulfate | DRUG | - |
| Amprenavir | DRUG | - |
| Efavirenz | DRUG | - |
| Adefovir dipivoxil | DRUG | - |
Inclusion Criteria You may be eligible for this study if you: * Are HIV-positive. * Had an HIV level of at least 2,000 copies/ml after 6 months of treatment with at least 1 PI other than amprenavir (meaning you failed PI treatment). * Are at least 13 years old (need consent of parent or guardian i...